Navigation Links
Hormone Reduces Mortality in Heart Patients With High BP
Date:3/29/2009

Relaxin cuts shortness of breath and trimmed hospital stays, phase 2 study concludes

SUNDAY, March 29 (HealthDay News) -- The hormone relaxin reduces shortness of breath and cardiovascular death in people with heart failure who also have high blood pressure, according to a phase 2 trial conducted in eight countries.

The study included 234 people who, within a few hours of arriving at a hospital, were randomly assigned to receive an intravenous infusion of a placebo or varying doses of relaxin -- 10, 30 100 or 250 micrograms/kilogram (µ/kg) -- a day.

Shortness of breath improved in 40 percent of those who were given 30 µ/kg, compared with 23 percent of those who received the placebo.

After 60 days, fewer people given 30 µ/kg of relaxin had died from a cardiovascular cause or had to be readmitted to the hospital because of heart or kidney failure than in the placebo group: 2.6 percent compared with 17.2 percent. After 180 days, there were no cardiovascular deaths in the relaxin group at this dosage, but 14.3 percent of the placebo group had died from cardiovascular causes, the study found.

The study also found that people in the relaxin 30 µ/kg group spent less time in the hospital than did those in the placebo group (10.2 days vs. 12 days) and lived longer after discharge (47.9 days vs. 44.2 days). No safety concerns were noted in the relaxin 30 µ/kg group.

The study was funded by Corthera, and several of the researchers worked for the biopharmaceutical company, which has the rights to develop and market relaxin. The findings were to be presented at the American College of Cardiology meeting in Orlando, Fla., and appear online and in an upcoming print issue of The Lancet.

Over time, standard therapy can resolve shortness of breath and high blood pressure caused by heart failure, but evidence from this study "suggests that early administration of this drug in addition to standard therapy might be associated with more rapid, sustained and complete resolution of acute heart failure, as well as with more favorable long-term outcomes," wrote Dr. John R. Teerlink, of the San Francisco Veterans Affairs Medical Center and his colleagues.

On the basis of the study's results, the researchers said they plan to conduct a phase 3 clinical trial of relaxin, at 30 µ/kg, in people with heart failure.

More information

The American Heart Association has more about heart failure.



-- Robert Preidt



SOURCE: The Lancet, news release, March 29, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Diplomat Specialty Pharmacy Expands National Growth Hormone Patient Care Program - Hires Denise Piro, RN, BSN
2. Hormone Might Help Restore Female Fertility
3. March 2009 Mayo Clinic Womens HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women
4. Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity
5. Obesity linked to hormone imbalance that impacts sexual quality of life
6. Hormone Drug May Help Drinkers Stay Sober
7. U of I study shows benefits of hormone found in fat tissue
8. Hormones May Help Shield Women from Parkinsons
9. UCSF Gallo Study Finds Hormone Disorder Drug Could Help Drinkers Stay Sober
10. Hormone linked to high blood pressure and blood vessel disease in African-Americans
11. Findings raise new questions about evolution of hormones in mammals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hormone Reduces Mortality in Heart Patients With High BP
(Date:2/20/2017)... ... February 20, 2017 , ... A new ... women are called back for additional examinations without sacrificing cancer detection, according to ... 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for ...
(Date:2/20/2017)... (PRWEB) , ... February 21, 2017 , ... Nancy ... offering readers a way to “ Getting Over the Bump in the Road ” ... and lessons learned on how to cope with the ups and downs experienced by ...
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... 213-8818 , Orbita, Inc., a leading provider of innovative software for connected home ... patient engagement and optimizing care journey management for home healthcare. , Built ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... a cloud-based self-service technology that runs on the Posiflex XT-series of touch screen ... during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Cognitive Computing for ... is allowing a previously unattainable level of personalized ... this ability, it is anticipated that the Global ... Billion by 2022. The growth of the market ... computing platforms, rising installation of cognitive computing software ...
(Date:2/21/2017)... Feb. 21, 2017  /PR Newswire/ -- UBM Medica,s ... announce the launch of Modern Retina ( ... retina specialists. Built upon the success of ... on the latest innovations in the areas of retinal ... management. By meeting current informational needs and filling existing ...
(Date:2/21/2017)... Scientists From Two Companies to Accelerate Development ... ... STEER, creator of advanced materials platform technologies that effectively ... pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, today announced a ... , a leading science & technology company, on ...
Breaking Medicine Technology: